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Abstract
Objectives—This study was designed to assess the relationship between insulin resistance and
incident heart failure (HF) in a community-based cohort.
Background—Diabetes mellitus increases the risk for HF, but the association between insulin
resistance and HF in individuals without diabetes is unclear.
Methods—We prospectively analyzed 12,606 participants without diabetes mellitus, prevalent
HF, or history of myocardial infarction at baseline (1987 to 1989) from the ARIC (Atherosclerosis
Risk in Communities) study. We assessed the relationship between insulin resistance and incident
HF using the homeostatic model assessment of insulin resistance (HOMA-IR) equation, adjusting
for age, sex, race, body mass index, smoking, hypertension, center, and interim myocardial
infarction. We tested for interactions by age, sex, obesity, and race.
Results—Participants with insulin resistance, defined as HOMA-IR ≥2.5 (n = 4,810, 39%), were
older, more likely female, African American, hypertensive, and had a higher body mass index as
compared with those without insulin resistance. There were 1,455 incident HF cases during a
median of 20.6 years of follow-up. Insulin resistance defined by this threshold was not
significantly associated with an increased risk for incident HF after adjustment (hazard ratio: 1.08,
95% confidence interval: 0.95 to 1.23). However, when analyzed continuously, this relationship
was nonlinear, which indicated that risk increased, and was significantly associated with incident
HF between HOMA-IR of 1.0 to 2.0, adjusting for baseline covariates; however, values over 2.5
were not associated with additional increased risk in adjusted models.
Conclusions—In a community cohort, insulin resistance, defined by lower levels of HOMA-IR
than previously considered, was associated with an increased risk for HF.
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Diabetes mellitus has been shown to be associated with a higher risk for incident heart
failure (HF) (1,2). Insulin resistance, with or without diabetes, has also been linked to an
elevated risk of HF (3), although this association has been inconsistent (4,5), due in part to
varying characteristics of study populations, differences in study follow-up time, or
dissimilar approaches to modeling the risk for HF and adjusting for covariates. Obesity,
known to be a primary determinant of insulin resistance, has also been independently
associated with incident HF (6,7). The relationship among obesity, insulin resistance, and
HF outcomes is unclear, as is the extent to which the HF risk associated with obesity may be
mediated by insulin resistance. Moreover, the association of insulin resistance with HF has
not been explored in a middle-aged cohort study with lengthy follow-up. The objectives of
this study were to investigate the association of insulin resistance with incident HF and to
explore whether factors such as obesity, age, sex, or race modified this association.
Methods
Participants
The ARIC (Atherosclerosis Risk in Communities) study is an ongoing community-based
cohort of 15,792 patients, comprised mostly of Caucasian and African-American men and
women, age 45 to 64 years at baseline (1987 to 1989), and sampled from 4 U.S.
communities: Forsyth County, North Carolina; the northwest suburbs of Minneapolis,
Minnesota; Washington County, Maryland; and Jackson, Mississippi (8). Standardized
physical examinations and interviewer-administered questionnaires were conducted at
baseline and at 3 triennial follow-up examinations (visit 2 [1990 to 1992], visit 3 [1993 to
1995], and visit 4 [1996 to 1998]). Participant follow-up through annual telephone
interviews, hospitalization, and vital status is ongoing. Individuals with prevalent HF (n =
752) or who were missing data to determine prevalent HF (n = 287), those with prevalent
diabetes (n = 1,870), or those with a history of myocardial infarction (MI) (n = 653) at
baseline were excluded. Prevalent HF was defined as follows (7): 1) those answering “yes”
to the question, “Were any of the medications you took during the last 2 weeks for HF?” or
2) those with stage 3 HF by applying Gothenburg criteria. Prevalent diabetes was defined as
fasting plasma glucose >126 mg/dl, nonfasting glucose >200 mg/dl, self-reported use of
diabetes medications, or self-reported physician diagnosis of diabetes. The remaining 12,606
participants were included in this analysis; follow-up time was 20.6 years. The protocol was
approved by each site’s institutional review board, and all participants provided written
informed consent in accordance with established guidelines for the protection of human
subjects.
Exposure definitions and baseline covariates
The homeostatic model assessment of insulin resistance (HOMA-IR) index was calculated
from fasting glucose and insulin at visit 1 using the following equation: (fasting glucose
[mg/dl] × fasting insulin [uIU/ml])/405 (9). Normal HOMA-IR index has previously been
reported as 1.0, although it ranges in healthy individuals from 1.0 to 1.5 and varies by age,
sex, and characteristics of the population sampled (9,10). All covariates were collected from
the baseline visit. Race was self-reported; smoking status was obtained from interviewer-
administered questionnaires.
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Incident HF was defined as the first HF hospitalization identified with International
Classification of Diseases–Ninth Revision discharge codes of 428.x in any position on the
hospital discharge list or a death certificate with death from HF in any position. HF
hospitalization and vital status data were available from study baseline through December
31, 2009.
Statistical analysis
Based on the traditional definition of insulin resistance (HOMA-IR ≥2.5) (9), we delineated
2 HOMA-IR categories prior to further analyses: <2.5, and ≥2.5. Baseline demographics
between participants in the 2 HOMA-IR categories were compared to identify potential
differences. Between-group assessments were performed using unpaired t tests or Wilcoxon
rank sum tests for continuous variables and chi-square or Fisher exact tests, as appropriate,
for categorical variables.
Logistic regression was used to examine characteristics that were associated with insulin
resistance (HOMA-IR ≥2.5) at baseline, adjusting for age, sex, body mass index (BMI) (as a
continuous variable), current smoking, hypertension, and center. In order to assess the
relationship between baseline HOMA-IR values and incident HF, multiple Cox proportional
hazards models were fit in each case, allowing the association with HOMA-IR to be
modeled flexibly through the use of restricted cubic splines. Two models were constructed:
model 1 adjusted for age and sex, and model 2 also adjusted for race, BMI, smoking,
hypertension, and center. As incident MI is a known factor in the pathway for development
of HF, we adjusted for incident MI as a time-varying covariate with model 2. As a
sensitivity analysis, we assessed the association of HOMA-IR with incident HF while
censoring individuals at the time of MI after visit 1. Unadjusted and adjusted models were
fit, and for each a baseline HOMA-IR value of 1.0 was used as the reference point. These
models were then refit using the common threshold value of HOMA-IR >2.5 to obtain a
more interpretable model. The utility and model fit using the standard cutoff value of 2.5
was then compared with other possible cutoff values, ranging from 1.0 to 3.0. Baseline risk
for incident HF was modeled using the covariates age, sex, race, BMI, smoking,
hypertension, center, and systolic blood pressure. A Cox model was fit, and the resulting
estimates provided a baseline risk score for each participant. As an exploratory analysis, we
investigated the association between fasting insulin and incident HF. Fasting insulin was
log-transformed and was examined in Cox proportional hazards models. The first model
adjusted for age and sex, and an expanded model further adjusted for race, BMI, smoking,
hypertension, center, and incident MI as a time-varying covariate. To estimate and compare
population attributable risks (PARs) between blood pressure measures and HOMA-IR, we
created a modified version of our fully-adjusted model, in which the linear systolic and
diastolic blood pressure terms were replaced with a single indicator of “elevated blood
pressure” (systolic blood pressure ≥140 mm Hg), and our HOMA-IR terms were replaced
with a single indicator of “elevated HOMA-IR” (HOMA-IR ≥2.0). Thereafter, the PAR was
calculated following elimination of each of these risk factors while keeping all other terms
in the model constant. Overall model performance of the HOMA-IR spline models was
evaluated with the C-statistic, removing MI as a time-varying covariate. Finally, interactions
among baseline HOMA-IR (modeled via cubic splines), baseline covariates (age 55 years or
older, sex, and race [African American or Caucasian]), and obesity (defined as BMI ≥30 kg/
m2) were assessed, as well as interactions between baseline HOMA-IR and estimated
baseline risk of HF. All analyses were conducted using Stata version 11 (StataCorp LP,
College Station, Texas).
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Demographic characteristics of participants by category of HOMA-IR are shown in Table 1.
Individuals with HOMA-IR ≥2.5, as compared with those within the noninsulin resistant
category (HOMA-IR <2.5), were more likely African American, had higher BMI, were
more likely hypertensive, and exhibited lower HDL and higher triglyceride values.
Characteristics that were significantly associated with insulin resistance at baseline in an
adjusted model included BMI, hypertension, female sex, older age, and African-American
race (Table 2).
There were 1,455 cases of incident HF during a median follow-up of 20.6 years. When
HOMA-IR was examined in relation to incident HF with a Cox proportional hazards model
via flexible cubic spline terms (Fig. 1), crude and adjusted models suggested an increasing
hazard associated with increasing HOMA-IR across the observed range beyond
approximately 1.0. In models adjusting for baseline covariates and interim MI as a time-
varying covariate, we observed a significant nonlinear relationship between HOMA-IR level
and the risk for HF (overall spline model C-statistic = 0.76, p = 0.024), with increasing
hazard from approximately 1.0 to just above 2.0, after which we observed no additional
hazard with increasing HOMA-IR. Table 3 compares the hazard ratio (HR) for incident HF
associated with the traditional threshold of HOMA-IR ≥2.5 in both the adjusted and
unadjusted models with alternative potential cutoff values, ranging from HOMA-IR ≥1.0 to
HOMA-IR ≥3.0. In age- and sex-adjusted models, all HOMA-IR values were associated
with incident HF. In fully-adjusted models, only HOMA-IR values 1.5, 2.0, and 2.25 were
significantly associated with incident HF, suggesting that the independent association
between HOMA-IR and incident HF is maintained only within this range. When the MI
time-varying covariate was removed from model 2, findings were similar to those of the
model that included MI, such that significant associations between HOMA-IR and incident
HF were only observed for HOMA-IR values 1.5, 2.0, and 2.25 (results not shown). Fasting
insulin alone was associated with incident HF in the model adjusted for age and sex (HR:
1.45, 95% confidence interval [CI]: 1.34 to 1.58), but not in fully-adjusted models (HR:
1.03, 95% CI: 0.94 to 1.13). The population-attributable risk for HOMA-IR at a threshold of
2.0 was 9% (95% CI: 2% to 16%), which was statistically comparable to the PAR of blood
pressure of 7% (95% CI: 4% to 10%), at a threshold of 140/90 mm Hg.
In subgroup analyses, nonsignificant trends were noted for interactions between HOMA-IR
and incident HF for age, sex, and estimated baseline risk of HF (p interactions = 0.07, 0.08,
and 0.1, respectively), such that the relationship between HOMA-IR and incident HF was
stronger for younger individuals, females, and those with lower baseline risk for HF
compared with those over age 55 years, males, and individuals with high baseline risk for
HF (Fig. 2). Of note, obesity and race did not modify the relationship between insulin
resistance and HF, and conversely, insulin resistance did not modify the very significant
relationship between obesity and HF incidence.
Discussion
We found in a community-based cohort that insulin resistance, based on HOMA-IR, was
associated with an increased risk of incident HF among those without diabetes at baseline.
This risk appeared to occur at lower levels than the previously-defined insulin resistance
threshold of a HOMA-IR of 2.5 and was not modified by race or BMI, but the relationship
between insulin resistance and HF was stronger in younger participants, in females, and in
those with lower baseline risk of HF. However, the association between insulin resistance
and HF was no longer significant at HOMA-IR levels ≥2.5. Interim MI did not mediate the
association between insulin resistance and HF.
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The relationship between insulin resistance and incident HF has varied in prior studies. Our
findings of a significant association between HOMA-IR, modeled flexibly with the use of
cubic splines, and incident HF following adjustment for risk factors for HF corroborate a
recent analysis of the Cardiovascular Health Study, which also found significant
associations between multiple measures of insulin resistance (fasting insulin, HOMA-IR
levels, and oral glucose tolerance testing) and incident HF in an older adult cohort (11).
Similar to the Cardiovascular Health Study, we found that insulin levels alone were less
predictive of HF than other measures of insulin resistance. It is possible that the combination
of hyperglycemia and hyperinsulinemia confers a higher risk, as hyperglycemia develops
when insulin levels can no longer reduce glucose levels sufficiently. In contrast, another
analysis of a large epidemiologic cohort study did not detect associations of metabolic
variables with incident HF (5). In that study, HOMA-IR scores were log-transformed and
assessed continuously, and values greater than the 95th percentile were only marginally
associated with incident HF. Another analysis of glycemic measures and incident HF in
individuals older than age 70 years noted significant associations with fasting glucose, but
not with HOMA-IR (4). In a study of older adult Swedish men, HOMA-IR was associated
with incident HF in unadjusted models, but not adjusted models (3). However, individuals
who exhibited higher oral glucose tolerance test values and lower euglycemic insulin clamp
disposal rates had a higher risk, still suggesting that insulin resistance as a whole may be
linked to incident HF. Differences in the effect of multivariable adjustment on the
relationship between insulin resistance and HF likely reflects differences in patient
populations, including differences in baseline risk, different lengths of follow-up time,
various ascertainment methods for HF events, and different available covariates.
We found that the relationship between insulin resistance and incident HF was nonlinear,
and in adjusted models, this risk began earlier than the traditionally used HOMA-IR index
cut-point of 2.5, but not when HOMA-IR was ≥2.5. The established threshold of HOMA-IR
2.5 to define insulin resistance is based on studies validating HOMA-IR against the
euglycemic hyperinsulinemic clamp technique and intravenous glucose tolerance tests
(9,12). Howe ver, our data suggest that other risk factors attenuate the relationship between
insulin resistance and incident HF when HOMAIR rises above approximately the traditional
cut-point of 2.5, and the greater contribution of other risk factors, such as increased BMI and
hypertension, at higher HOMA-IR levels may dilute the effect of insulin resistance.
Moreover, it is possible that because of the large number of participants in the HOMA-IR
1.5 to 2.5 range in the ARIC study, we had greater power to detect an association between
lower levels of insulin resistance and incident HF than prior studies. Obesity has previously
been associated with incident HF in epidemiologic studies, including the ARIC
study(6,7,13–15). The relationship among obesity, insulin resistance, and HF is complex,
and it is difficult to separate causative associations with these related risk factors. However,
in our analysis, insulin resistance was associated with incident HF independent of BMI, and
this relationship was not modified by obesity, suggesting that metabolic derangements
beyond obesity may play an important role in target organ damage. Although a recent study
has suggested that metabolically-healthy obese people may have a reduced risk for HF (16),
in our analysis, obesity was associated with incident HF, and this relationship was also not
modified by insulin resistance, suggesting that obesity with or without insulin resistance
remained a risk factor for incident HF.
A number of mechanisms may explain the association between insulin resistance and HF.
Although insulin resistance and abnormalities of glycemic control have been associated with
increased risk for MI, which itself is a key mediator in the development of HF, our results
suggest that this relationship was not dependent on interim MI, and suggests a more direct
potential mechanism relating insulin resistance and the development of HF. The
myocardium utilizes free fatty acids and less glucose in the setting of insulin resistance (17).
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This metabolic irregularity increases vulnerability to pressure overload or ischemia. Insulin
is a recognized growth factor and has been shown to facilitate cardiac remodeling (18–20).
Hyperinsulinemia also leads to sodium retention (21), which can potentially cause fluid
retention. Moreover, higher insulin levels activate the sympathetic nervous system (22).
Insulin resistance has been linked to a more pronounced response to angiotensin II, which
may contribute to alterations in cardiac structure (23). However, an elevation in insulin may
simply be a marker of metabolic derangement, and may not itself mediate the progression to
heart disease.
Study limitations
As with any observational cohort study, residual confounding remains of concern.
Identification of HF cases relied on International Classification of Diseases–Ninth Revision
codes, which may not accurately reflect HF incidence. Death due to HF was determined
from death certificates, which may overestimate or underestimate the number of cases.
Additionally, the type of HF was not recorded. However, validation of HF hospitalizations
indicated that the positive predictive value of 428.x in the first position was 93% for acute
decompensated HF and 97% for chronic HF (24). It is possible that other methods of
measuring insulin resistance, such as euglycemic clamping or the intravenous glucose
tolerance test, could have yielded different results, although these are impractical in a large
cohort study. The HOMA-IR equation has been validated in normoglycemic individuals
against insulin sensitivity assessed directly from the euglycemic-hyperinsulinemic clamp
technique and has been widely used in epidemiological studies. Because the ARIC study
consisted of a middle-age community in the United States, additional studies are needed in
younger populations, older adults, or other ethnicities. Finally, although our data suggest
that HF risk associated with insulin resistance may begin at a lower level than previously
considered, it was not our intention to establish an alternative lower cutoff point for HOMA-
IR, as the relationship between lower levels of HOMA-IR and incident HF will need to be
assessed in additional cohorts and examined in relation to different outcomes.
Conclusions
In a community cohort, insulin resistance, beginning at a lower HOMA-IR level than
previously established but not when HOMA-IR was ≥2.5, was associated with incident HF
and was not mediated by an increased risk of MI. Moreover, this relationship was not
modified by BMI, suggesting that there is an independent role for insulin resistance on
increasing risk for cardiac disease beyond obesity.
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Figure 1. Distribution of HOMA-IR Levels and Relationship Between HOMA-IR and Incident
Heart Failure
Distribution of homeostatic model assessment of insulin resistance (HOMA-IR) levels
(histogram, right axis) and the continuous relationship between HOMA-IR levels and
incident heart failure (splines, with 95% confidence intervals, left axis). A shows the
relationship adjusted for age and sex (p < 0.001), and B shows the adjusted relationship (p =
0.024).
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Figure 2. Subgroup Comparisons Showing Relationship Between Insulin Resistance and Incident
Heart Failure
Subgroup comparisons showing relationship between insulin resistance and incident heart
failure with (A) age; (B) sex; and (C) baseline risk for incident heart failure, in adjusted
models. HOMA-IR = homeostatic model assessment of insulin resistance.
Vardeny et al. Page 10

























Vardeny et al. Page 11
Table 1
Baseline Characteristics by HOMA-IR Category
Characteristic HOMA-IR <2.5(n = 7,566)
HOMA-IR ≥2.5
(n = 4,810) p Value
Age, yrs 54 ± 5.7 54 ± 5.7
Male 3,144 (42.0) 2,309 (48.0) <0.001
Caucasian 6,152 (81.3) 3,288 (68.4) <0.001
Body mass index (kg/m2) 25 ± 3.8 30 ± 5.3 <0.001
Current smoker 2,125 (28) 1,053 (21.9) <0.001
Hypertension 1,616 (21) 1,978 (41.2) <0.001
Fasting glucose, mg/dl 95 ± 8.0 103 ± 9.0 <0.001
Fasting insulin, uIU/ml 6.4 ± 2.4 17.4 ± 8.7 <0.001
LDL cholesterol, mg/dl 134 ± 39 141 ± 39 <0.001
HDL cholesterol, mg/dl 57 ± 17 47 ± 14 <0.001
Triglycerides, mg/dl 106 ± 56 150 ± 95 <0.001
eGFR, ml/min/1.73 m2 93 ± 19 92 ± 22 0.35
Values are mean ± SD or n (%).
eGFR = estimated glomerular filtration rate; HDL = high-density lipoprotein; HOMA-IR = homeostatic model assessment of insulin resistance;
LDL = low-density lipoprotein.
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Table 2
Characteristics Associated With Insulin Resistance* at Baseline
Characteristic Odds Ratio (95% CI) Z score p Value
BMI (per kg/m2) 1.30 (1.29–1.31) 48.2 <0.001
Hypertension 1.90 (1.79–2.11) 15.3 <0.001
Female sex 0.77 (0.70–0.82) 7.0 <0.001
Age (per yr) 1.02 (1.02–1.03) 6.98 <0.001
Black race 1.37 (1.25–1.51) 6.72 <0.001
Current smoking 0.97 (0.89–1.06) 0.7 0.48
*
Defined as homeostatic model assessment of insulin resistance ≥2.5.
BMI = body mass index; CI = confidence interval.
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Table 3








1.00 1.34 (1.12–1.61) 0.001 0.95 (0.79–1.14) 0.564
1.25 1.53 (1.32–1.78) <0.001 1.13 (0.97–1.33) 0.115
1.50 1.58 (1.39–1.80) <0.001 1.15 (1.00–1.32) 0.046
1.75 1.55 (1.38–1.74) <0.001 1.11 (0.98–1.26) 0.094
2.00 1.61 (1.44–1.79) <0.001 1.15 (1.02–1.30) 0.022
2.25 1.67 (1.50–1.85) <0.001 1.17 (1.04–1.31) 0.010
2.50 1.58 (1.43–1.76) <0.001 1.10 (0.97–1.23) 0.127
2.75 1.55 (1.40–1.72) <0.001 1.05 (0.93–1.18) 0.465
3.00 1.51 (1.35–1.68) <0.001 1.01 (0.89–1.14) 0.925
*
Model 1 adjusted for age and female sex.
†
Model 2 adjusted for age, female sex, race, BMI, smoking, hypertension, study center, and myocardial infarction as time-varying covariate.
HF = heart failure; HOMA-IR = homeostatic model assessment of insulin resistance; HR = hazard ratio; other abbreviations as in Table 2.
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